PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 7, 2021Proceedings of the National Academy of Sciences129 citationsOpen Access

A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry

JVJulián ValeroLCLaia CivitDDDaniel M. Dupont

Structured PICO

Does a 2'-fluoro protected RNA aptamer neutralize viral entry in SARS-CoV-2 cell culture models?

P
Population
In vitro models including virus-like particles and live SARS-CoV-2 in cell culture
I
Intervention
2'-fluoro protected RNA aptamer (monomeric and trimerized versions) targeting the receptor binding domain (RBD) of SARS-CoV-2 spike protein
O
Outcome
Binding affinity to SARS-CoV-2 spike protein and neutralization of viral entry/infectionsurrogate

A novel 2'-fluoro protected RNA aptamer demonstrates high-affinity binding to the SARS-CoV-2 spike protein and effectively neutralizes viral entry in vitro.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has created an urgent need for new technologies to treat COVID-19. Here we report a 2'-fluoro protected RNA aptamer that binds with high affinity to the receptor binding domain (RBD) of SARS-CoV-2 spike protein, thereby preventing its interaction with the host receptor ACE2. A trimerized version of the RNA aptamer matching the three RBDs in each spike complex enhances binding affinity down to the low picomolar range. Binding mode and specificity for the aptamer-spike interaction is supported by biolayer interferometry, single-molecule fluorescence microscopy, and flow-induced dispersion analysis in vitro. Cell culture experiments using virus-like particles and live SARS-CoV-2 show that the aptamer and, to a larger extent, the trimeric aptamer can efficiently block viral infection at low concentration. Finally, the aptamer maintains its high binding affinity to spike from other circulating SARS-CoV-2 strains, suggesting that it could find widespread use for the detection and treatment of SARS-CoV-2 and emerging variants.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Valero et al. (2021) studied this question.

synapsesocial.com/papers/69faa2e63cd444e92178daf0https://doi.org/10.1073/pnas.2112942118
Ask AI
Helpful
Bookmark
Share
View Full Paper